Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival

Kaspar René Nielsen(Aalborg University Hospital), Hans Erik Johnsen(Herlev Hospital), Ulla Vogel(National Research Centre for the Working Environment), Kim Steve Bergkvist(Chr. Hansen (Denmark)), María Rodrigo-Domingo(Chr. Hansen (Denmark)), Alexander Schmitz(Chr. Hansen (Denmark)), Rudi Steffensen(Aalborg University Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Annette Juul Vangsted(Copenhagen University Hospital), Martin Bøgsted(Chr. Hansen (Denmark)), Preben Johansen(Chr. Hansen (Denmark)), Karen Dybkær(Aalborg University Hospital), John Bæch(Aalborg University Hospital), Liesbeth Oosterhof(Aalborg University Hospital)
Leukemia & lymphoma/Leukemia and lymphoma
April 9, 2017
10.1080/10428194.2017.1306643
Cited by 13

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
|Blood|2009|390
Genotoxicity, cytotoxicity, and reactive oxygen species induced by single‐walled carbon nanotubes and C<sub>60</sub> fullerenes in the FE1‐Muta™Mouse lung epithelial cells
|Environmental and Molecular Mutagenesis|2008|372